Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.

@article{Cebere2006PhaseIC,
  title={Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.},
  author={Inese Cebere and Lucy Dorrell and Helen McShane and Alison Simmons and Sheena McCormack and Claudia L. Schmidt and Carol M Smith and Mary Brooks and Joanna E Roberts and Simon C Darwin and Patricia E. Fast and Christopher Conlon and Sarah L Rowland-Jones and Andrew J McMichael and Tom{\'a}{\vs} Hanke},
  journal={Vaccine},
  year={2006},
  volume={24 4},
  pages={417-25}
}
DNA- and modified virus Ankara (MVA)-vectored candidate vaccines expressing human immunodeficiency virus type 1 (HIV-1) clade A-derived p24/p17 gag fused to a string of HLA class I epitopes, called HIVA, were tested in phase I trials in healthy, HIV-1/2-uninfected adults in Oxford, United Kingdom. Eighteen volunteers were vaccinated with pTHr.HIVA DNA (IAVI-001) alone, 8 volunteers received MVA.HIVA (IAVI-003) alone and 9 volunteers from study IAVI-001 were boosted with MVA.HIVA 9-14 months… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 48 extracted citations

Similar Papers

Loading similar papers…